Ocular Therapeutix insider files to sell 9,653 shares on NASDAQ

Rhea-AI Filing Summary

OCULAR THERAPEUTIX, INC. (OCUL) filed a Form 144 notifying a proposed sale of 9,653 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $106,516.03. The sale is scheduled approximately for 10/02/2025 on NASDAQ. The shares were acquired on 10/01/2025 as restricted stock vesting under a registered plan and payment (if any) is noted as Not Applicable. The filing names Peter Kazuo Kaiser as a seller who previously sold 3,011 shares on 08/25/2025 for $36,252.74. The notice includes the seller's representation that they are not aware of undisclosed material adverse information about the issuer.

Positive

• Form 144 filed, indicating regulatory compliance and disclosure of the proposed sale
• Shares to be sold were acquired via restricted stock vesting on 10/01/2025, showing a clear acquisition record

Negative

• Insider Peter Kazuo Kaiser plans to sell 9,653 shares valued at $106,516.03, which may increase share supply
• A prior insider sale of 3,011 shares on 08/25/2025 for $36,252.74 indicates recent sell activity

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	9653	106516.03	173995221	10/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/01/2025	Restricted stock vesting under a registered plan	Issuer			9653	10/01/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
PETER KAZUO KAISER 15 Crosby Drive Bedford MA 01730	Common	08/25/2025	3011	36252.74

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the OCUL Form 144 report?

It reports a proposed sale of 9,653 common shares valued at $106,516.03, to be sold approximately on 10/02/2025 on NASDAQ.

Who is the seller named in the filing for OCUL?

The filing identifies Peter Kazuo Kaiser as a seller and reports a prior sale of 3,011 shares on 08/25/2025.

How were the shares to be sold acquired?

The 9,653 shares were acquired on 10/01/2025 as restricted stock vesting under a registered plan.

Through which broker will the OCUL shares be sold?

The proposed sale lists Morgan Stanley Smith Barney LLC as the broker, located at 1 New York Plaza, 8th Floor, New York, NY.

Does the Form 144 state any undisclosed material information about OCUL?

The filer represents by signature that they do not know any material adverse information about the issuer that has not been publicly disclosed.